Issues involving testing surround all parts of the COVID-19 pandemic: testing as a containment strategy, accuracy of tests, availability of tests, the regulations for tests, future uses for tests – and more. Hear about the past and future of COVID-19 testing from two experts with decades of experience in the legal, business, and medical sides of novel biotechnology development.

Want to watch it again, or unable to join us live? You can enjoy recordings of the event here:

Watch Event

About the Speakers

Dr. Linda Grais, JD ’93

Dr. Grais has more than 20 years of experience in clinical medicine, drug development, and the biopharmaceutical industry as a physician, entrepreneur, and investor. She was President, CEO, and a member of the Board of Directors of Ocera Therapeutics (OCRX) from 2012 until its acquisition by Mallinckrodt in December, 2017. Dr. Grais currently serves on the Boards of Directors of Arca Biopharma, Corvus Pharma, PRA Health Sciences, and Zosano Pharma. In addition to her JD from Stanford Law School, she holds a BA from Yale University, Magna Cum Laude and Phi Beta Kappa, and an MD from Yale Medical School.

Professor Hank Greely, BA ’74

Professor Greely is the Deane F. and Kate Edelman Johnson Professor of Law, a professor (by courtesy) of genetics at Stanford School of Medicine, and director of the Center for Law and Biosciences. He specializes in the ethical, legal, and social implications of new biomedical technologies, particularly those related to neuroscience, genetics, or stem cell research. He is a founder and past president of the International Neuroethics Society; a member of the Multi-Council Working Group of the NIH’s BRAIN Initiative, whose Neuroethics Working Group he co-chairs; a former member of the Committee on Science, Technology, and Law of the National Academies; and chair of California’s Human Stem Cell Research Advisory Committee. In addition to his BA from Stanford University, he holds a JD from Yale Law School.